Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07327489 · ClinicalTrials.gov registry record
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies
A clinical trial of Cancer and Colorectal Cancer, sponsored by Elephas.
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 8
- Study locations
NCT07327489: Recruiting study of Cancer and Colorectal Cancer, sponsored by Elephas.
NCT07327489 is a study of Cancer and Colorectal Cancer that is actively recruiting participants, run by Elephas. The registered enrollment target is 2,000 participants, below the 3,488-participant average among 615 other Cancer trials with a reported enrollment target (43% lower). The trial reports 8 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07327489, a study of Cancer and Colorectal Cancer, is actively recruiting participants, sponsored by Elephas.
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 8
- Study locations
Study Summary
This study will collect tumor specimens with correlated clinical and demographic data from patients who are undergoing a biopsy or similar procedure to obtain tumor tissue as a normal course of their medical management or diagnostic work-up for suspected or confirmed cancer.
Primary Outcome
Collect human tumor specimens to research mechanisms of tumor cutting, imaging, and ex-vivo immunotherapy treatment response, while maintaining cell stability in a live tumor microenvironment.
Conditions Studied
Interventions
- PROCEDURE Biopsy
Study Locations (8)
Missouri
- Mercy Hospital - SPG - Springfield
- Mercy Hospital - South - St Louis
- Mercy Hospital -STL - St Louis
Texas
- JPS Health Network - Forth Worth
- Baylor Scott and White Biorepository - Temple
Arkansas
- Mercy Hospital - FTS - Fort Smith
Maryland
- Frederick Health Hospital - Frederick
Oklahoma
- Mercy Hospital - OKC - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2025-04-14 |
| Est. Completion | 2038-04 |
What NCT07327489 shows while recruiting
NCT07327489 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, below the 3,488-participant average among 615 other Cancer trials with a reported enrollment target (43% lower).
The record links to 10 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Biopsy is the first listed.
NCT07327489 lists 8 locations in 5 states (Missouri, Texas, Arkansas).
Frequently Asked Questions
What is clinical trial NCT07327489 about?
NCT07327489 is a clinical study titled "Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies". This study will collect tumor specimens with correlated clinical and demographic data from patients who are undergoing a biopsy or similar procedure to obtain tumor tissue as a normal course of their medical management or diagnostic work-up for suspected or confirmed cancer.
What is the current status of trial NCT07327489?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2025-04-14. Estimated completion is 2038-04.
What conditions does trial NCT07327489 study?
This clinical trial studies the following conditions: Cancer, Colorectal Cancer, Head and Neck Cancer, Endometrial Cancer, Bladder Cancer.
What interventions are being tested in trial NCT07327489?
The interventions under investigation include: Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT07327489?
This trial is sponsored by Elephas, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07327489 being conducted?
This trial has 8 study locations across Arkansas, Maryland, Missouri, Oklahoma, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07327489's enrollment target sits among peer trials
2,000 56th of 615 higher than 553 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI